IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Trial Details

NCT ID
NCT05365659
Phase
PHASE1
Sponsor
Iksuda Therapeutics Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • IKS03
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Hobart, Tasmania, Australia|-42.87936,147.32941
  • Perth, Western Australia, Australia|-31.95224,115.8614

Key Eligibility Criteria

  • Males or females, ≥ 18 years of age
  • Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confir…
  • Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:
  • Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →